Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Liabilities: 2014-2024

Historic Total Liabilities for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $28.0 million.

  • Viking Therapeutics' Total Liabilities fell 0.21% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year decrease of 0.21%. This contributed to the annual value of $28.0 million for FY2024, which is 39.72% up from last year.
  • Latest data reveals that Viking Therapeutics reported Total Liabilities of $28.0 million as of FY2024, which was up 39.72% from $20.1 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Total Liabilities peaked at $28.0 million during FY2024, and registered a low of $8.8 million during FY2021.
  • For the 3-year period, Viking Therapeutics' Total Liabilities averaged around $23.8 million, with its median value being $23.2 million (2022).
  • As far as peak fluctuations go, Viking Therapeutics' Total Liabilities decreased by 27.80% in 2021, and later soared by 164.38% in 2022.
  • Viking Therapeutics' Total Liabilities (Yearly) stood at $12.2 million in 2020, then decreased by 27.80% to $8.8 million in 2021, then soared by 164.38% to $23.2 million in 2022, then decreased by 13.51% to $20.1 million in 2023, then soared by 39.72% to $28.0 million in 2024.